405 related articles for article (PubMed ID: 34386430)
1. Prostate Cancer Progression: as a Matter of Fats.
Scaglia N; Frontini-López YR; Zadra G
Front Oncol; 2021; 11():719865. PubMed ID: 34386430
[TBL] [Abstract][Full Text] [Related]
2. Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer.
Chetta P; Zadra G
Cancer Drug Resist; 2021; 4(1):143-162. PubMed ID: 35582011
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. The fat side of prostate cancer.
Zadra G; Photopoulos C; Loda M
Biochim Biophys Acta; 2013 Oct; 1831(10):1518-32. PubMed ID: 23562839
[TBL] [Abstract][Full Text] [Related]
5. The ADAM9/UBN2/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer.
Le TT; Hsieh CL; Lin IH; Chu CY; Do AD; Chen SH; Shigemura K; Kitagawa K; Fujisawa M; Liu MC; Chen KC; Sung SY
Am J Cancer Res; 2022; 12(1):176-197. PubMed ID: 35141012
[TBL] [Abstract][Full Text] [Related]
6. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Gui B; Gui F; Takai T; Feng C; Bai X; Fazli L; Dong X; Liu S; Zhang X; Zhang W; Kibel AS; Jia L
Proc Natl Acad Sci U S A; 2019 Jul; 116(29):14573-14582. PubMed ID: 31266892
[TBL] [Abstract][Full Text] [Related]
7. Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?
Chetta P; Sriram R; Zadra G
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444583
[TBL] [Abstract][Full Text] [Related]
8. Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor's Immune Environment.
Siltari A; Syvälä H; Lou YR; Gao Y; Murtola TJ
Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077824
[TBL] [Abstract][Full Text] [Related]
9. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
[No Abstract] [Full Text] [Related]
10. Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis.
Li S; Kang Y; Zeng Y
Biochim Biophys Acta Rev Cancer; 2024 Jan; 1879(1):189033. PubMed ID: 38040267
[TBL] [Abstract][Full Text] [Related]
11. New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.
Zadra G; Priolo C; Patnaik A; Loda M
Clin Cancer Res; 2010 Jul; 16(13):3322-8. PubMed ID: 20423984
[TBL] [Abstract][Full Text] [Related]
12. Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer.
Miro C; Di Giovanni A; Murolo M; Cicatiello AG; Nappi A; Sagliocchi S; Di Cicco E; Morra F; Celetti A; Pacifico F; Imbimbo C; Crocetto F; Dentice M
Cancer Lett; 2022 Apr; 532():215581. PubMed ID: 35134514
[TBL] [Abstract][Full Text] [Related]
13. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
Zhou L; Zhang C; Yang X; Liu L; Hu J; Hou Y; Tao H; Sugimura H; Chen Z; Wang L; Chen K
Clin Transl Med; 2021 Jun; 11(6):e449. PubMed ID: 34185414
[TBL] [Abstract][Full Text] [Related]
14. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.
Tamura K; Makino A; Hullin-Matsuda F; Kobayashi T; Furihata M; Chung S; Ashida S; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2009 Oct; 69(20):8133-40. PubMed ID: 19826053
[TBL] [Abstract][Full Text] [Related]
15. Androgens and the control of lipid metabolism in human prostate cancer cells.
Swinnen JV; Verhoeven G
J Steroid Biochem Mol Biol; 1998 Apr; 65(1-6):191-8. PubMed ID: 9699873
[TBL] [Abstract][Full Text] [Related]
16. Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics.
Chianese U; Papulino C; Passaro E; Evers TM; Babaei M; Toraldo A; De Marchi T; Niméus E; Carafa V; Nicoletti MM; Del Gaudio N; Iaccarino N; Randazzo A; Rotili D; Mai A; Cappabianca S; Mashaghi A; Ciardiello F; Altucci L; Benedetti R
Mol Metab; 2022 Oct; 64():101561. PubMed ID: 35944897
[TBL] [Abstract][Full Text] [Related]
17. Macrophage inhibitory cytokine-1 induced by a high-fat diet promotes prostate cancer progression by stimulating tumor-promoting cytokine production from tumor stromal cells.
Huang M; Narita S; Koizumi A; Nara T; Numakura K; Satoh S; Nanjo H; Habuchi T
Cancer Commun (Lond); 2021 May; 41(5):389-403. PubMed ID: 33773090
[TBL] [Abstract][Full Text] [Related]
18. Cancer-Associated Fibroblast: Role in Prostate Cancer Progression to Metastatic Disease and Therapeutic Resistance.
Bedeschi M; Marino N; Cavassi E; Piccinini F; Tesei A
Cells; 2023 Mar; 12(5):. PubMed ID: 36899938
[TBL] [Abstract][Full Text] [Related]
19. Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate
Zhou H; He Q; Li C; Alsharafi BLM; Deng L; Long Z; Gan Y
Front Cell Dev Biol; 2022; 10():955669. PubMed ID: 35938167
[TBL] [Abstract][Full Text] [Related]
20. Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance.
Zhong S; Huang C; Chen Z; Chen Z; Luo JL
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
